Release Therapeutics, a Geneva, Switzerland-based BioMedTech company, raised CHF3.3M in Seed funding.
Backers included undisclosed private investors.
The company intends to use the funds to expand operations and its R&D sector.
Led by CEO Thomas Mehrling, Release Therapeutics is a BioMedTech company developing cell macroencapsulation technology designed to deliver therapeutic proteins beyond the human blood-brain barrier. Its proprietary technology integrates an implantable macroencapsulation device with an immortalised myoblast cell line capable of producing a broad range of proteins for long-term delivery to the CNS.
The company’s lead programme is in preclinical development for the treatment of Metachromatic Leukodystrophy (MLD), a rare genetic disorder that leads to progressive loss of myelin and typically affects young children.
FinSMEs
07/08/2024